Analysts Set Expectations for CRGX FY2025 Earnings

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Equities researchers at Chardan Capital issued their FY2025 earnings estimates for CARGO Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings per share of ($3.59) for the year. Chardan Capital currently has a “Neutral” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for CARGO Therapeutics’ FY2026 earnings at ($3.58) EPS.

A number of other equities research analysts also recently weighed in on CRGX. William Blair downgraded CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. lowered shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Thursday, January 30th. HC Wainwright cut shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 30th. Truist Financial lowered shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the company from $32.00 to $7.00 in a report on Thursday, January 30th. Finally, Jefferies Financial Group lowered shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $32.00 to $3.00 in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.00.

CARGO Therapeutics Stock Up 0.2 %

Shares of NASDAQ CRGX opened at $4.18 on Thursday. The stock’s 50 day moving average price is $5.35 and its two-hundred day moving average price is $13.59. CARGO Therapeutics has a 52-week low of $3.00 and a 52-week high of $25.45. The stock has a market capitalization of $192.50 million, a P/E ratio of -0.98 and a beta of 1.65.

Hedge Funds Weigh In On CARGO Therapeutics

A number of institutional investors have recently bought and sold shares of CRGX. Charles Schwab Investment Management Inc. grew its holdings in shares of CARGO Therapeutics by 87.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 295,960 shares of the company’s stock valued at $5,460,000 after buying an additional 138,261 shares in the last quarter. FMR LLC grew its stake in shares of CARGO Therapeutics by 1.1% in the 3rd quarter. FMR LLC now owns 6,954,476 shares of the company’s stock valued at $128,310,000 after buying an additional 77,508 shares in the last quarter. BNP Paribas Financial Markets grew its position in CARGO Therapeutics by 437.8% in the third quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock worth $211,000 after acquiring an additional 9,311 shares in the last quarter. MetLife Investment Management LLC increased its position in CARGO Therapeutics by 59.3% during the third quarter. MetLife Investment Management LLC now owns 19,833 shares of the company’s stock worth $366,000 after buying an additional 7,380 shares during the last quarter. Finally, Sio Capital Management LLC bought a new position in shares of CARGO Therapeutics in the 3rd quarter valued at approximately $3,208,000. Hedge funds and other institutional investors own 93.16% of the company’s stock.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.